米拉制药公司宣布在治疗神经病痛方面取得突破 与Ketamir-2, 一种新型口服氯胺酮类比。 Mira Pharmaceuticals announces a breakthrough in treating neuropathic pain with Ketamir-2, a novel oral ketamine analog.
米拉制药公司展示了在治疗神经病痛方面的突破 其新型口服氯胺酮类比Ketamir-2。 Mira Pharmaceuticals reveals a breakthrough in treating neuropathic pain with their novel oral ketamine analog, Ketamir-2. 在临床前的一项研究中,Ketamir-2完全将大鼠的疼痛阈值正常化,实现神经病痛信号完全逆转。 In a pre-clinical study, Ketamir-2 fully normalized pain thresholds in rats, achieving a complete reversal of neuropathic pain signals. 该公司旨在评估Ketamir-2在治疗癌症引起的抑郁症和神经病痛方面的功效,目标是到2025年展示人类的功效。 The company aims to evaluate Ketamir-2's efficacy in treating cancer-induced depression and neuropathic pain, with the goal of demonstrating efficacy in humans by 2025.